Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZMYM2
REST API REST API
Homo sapiens
ZMYM2 is differentially expressed in 356 experiments: 143 organism parts: liver, prostate, ... (141 more);, 247 disease states: normal, glioblastoma, ... (245 more);, 123 cell types 474 cell lines 51 compound treatments and 86 other conditions.
Synonyms FIM, MYM, RAMP, ZNF198
Orthologs A6QLH9_BOVIN (Bos taurus)   D4A3R6_RAT (Rattus norvegicus)   Zmym2 (Mus musculus)   woc (Drosophila melanogaster)   ENSGALG00000017139 (Gallus gallus)   zmym2 (Xenopus laevis)   ZMYM2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, ubiquitin conjugating enzyme binding, metal ion binding, biological_process, nucleus, zinc ion binding, PML body
InterPro Term TRASH, Znf_MYM, DUF3504, TRASH_TR_C_arc
UniProt Accession Q9UBW7, Q5W0Q3, B4DZH0, C9JYC9
Search EB-eye ENSG00000121741
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
Jurkat
3
E-MEXP-2197, E-MTAB-62, E-GEOD-1880
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
HT1080
2
E-MTAB-37, E-GEOD-20089
468 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-2822, E-GEOD-21750, ... (59 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD33+ myeloid
2
E-TABM-145, E-AFMX-5
adipocyte
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-TABM-145, E-AFMX-5
CD34+
2
E-TABM-145, E-AFMX-5
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
117 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (71 experiments)

Factor Value U/D Experiments
astrocytoma
2
E-MTAB-37, E-GEOD-4290
benign prostatic hyperplasia
2
E-MEXP-1243, E-MEXP-2034
osteosarcoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
241 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, ... (33 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
none
6
7
E-TABM-868, E-TABM-782, E-GEOD-412, E-GEOD-5824, E-GEOD-7307, ... (13 experiments)
4,5-dianilinophthalimide
2
1
E-GEOD-5258
dimethyl sulfoxide
1
E-GEOD-6932
R547
1
E-GEOD-15389
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
45 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-MTAB-69, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-1059, E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (18 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307 ... (5 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-6532

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.449 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM